论文部分内容阅读
目的分析肿瘤抑制基因CMTM5甲基化在肾癌表达,为临床诊断治疗提供参考。方法检测肾癌细胞系和正常人肾细胞株中CMTM5的表达及甲基化水平。选取本院及部分苏大附一院肾癌患者为研究对象,检测患者血液、尿液中CMTM5的甲基化水平。征得患者同意后,肾癌患者手术治疗,留取标本,进行CMTM5的甲基化检测。结果正常人肾细胞株CMTM5蛋白阳性率显著高于肾癌细胞株(χ2=3.2641,P<0.05),CMTM5甲基化阳性率显著低于肾癌细胞株(χ2=3.6944,P<0.05)。肾癌组织中CMTM5蛋白阳性率(52.4%)显著低于正常肾组织(76.7%)(χ2=7.8889,P<0.05),CMTM5甲基化阳性率(73.0%)显著高于正常肾组织(48.3%)(χ2=7.8889,P<0.05),预后较差患者CMTM5表达较低。CMTM5甲基化表达与肾癌患者年龄、性别、病理分级无关,早期肾癌CMTM5甲基化表达显著低于Ⅲ期以后患者(χ2=6.3087,P<0.05)。结论 CMTM5在肾癌组织中表达下调,且和其甲基化程度密切相关。肾癌患者的血液或尿液标本能检测到CMTM5的甲基化,可能为肾癌的早期诊断提供新的参考。
Objective To analyze the expression of tumor suppressor gene CMTM5 in renal cell carcinoma and provide references for clinical diagnosis and treatment. Methods The expression and methylation of CMTM5 in renal cell carcinoma cell lines and normal human kidney cell lines were detected. We selected our hospital and some patients with renal cell carcinoma of the First Affiliated Hospital of Suzhou as the research object to detect the blood and urine of CMTM5 methylation levels. After obtaining the consent of the patients, the patients with renal cell carcinoma were treated by surgery, and specimens were taken for methylation detection of CMTM5. Results The positive rate of CMTM5 protein in normal renal cell line was significantly higher than that in renal cell carcinoma (χ2 = 3.2641, P <0.05). The positive rate of CMTM5 methylation was significantly lower than that in renal cell carcinoma (χ2 = 3.6944, P <0.05). The positive rate of CMTM5 protein in renal cell carcinoma (52.4%) was significantly lower than that in normal renal tissues (76.7%) (χ2 = 7.8889, P <0.05) %) (χ2 = 7.8889, P <0.05). CMTM5 expression in patients with poor prognosis was lower. CMTM5 methylation expression was not associated with age, sex and pathological grade of renal cell carcinoma. The methylation expression of CMTM5 in early stage renal cell carcinoma was significantly lower than that in stage Ⅲ patients (χ2 = 6.3087, P <0.05). Conclusion CMTM5 is down-regulated in renal cell carcinoma and closely related to the degree of methylation. Detection of CMTM5 methylation in blood or urine samples from patients with renal cell carcinoma may provide a new reference for the early diagnosis of renal cell carcinoma.